Phaseline

Companies › AnaptysBio

AnaptysBio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rosnilimab
PD-1 agonist antibody
PDCD1Phase 2Rheumatoid Arthritis; Ulcerative Colitis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06041269RosnilimabPhase 2Rheumatoid ArthritisImmunologyNov 2024
NCT06127043RosnilimabPhase 2Ulcerative ColitisImmunologyJan 2026

From the company's SEC filings

Cash and short-term investments of $286m on 2026-03-31; operating cash outflow about $106m a year; runway about 32 months at that burn, to Dec 2028

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

Q32 Bio RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Chengdu Kangnuoxing Biopharma Zura Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.